

DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies. **Indicates that this individual's presentation will include discussion of off-label or unapproved usage:

All of the relevant financial relationships listed for these individuals have been mitigated.

William Chey, M.D., has indicated that he is an employee for Michigan Medicine. He has also indicated that he received Grant/Research support from NIH, FDA, Biomerica, Commonwealth Diagnostics, QOL Medical, and Salix.

William Chey, M.D., has also indicated that he is a consultant for Abbvie, Allakos, Alnylam, Arena, Biomerica, Cosmo, Gemelli, IM Health, Ironwood, Nestle, QOL Medical, Phathom, Progenity, Redhill, Sali.

William Chey, M.D., also indicated that he is in an executive role for American College of Gastroenterology, GI Health Foundation, International Foundation of GI Disorders, Rome Foundation.

William Chey, M.D., also owns individual stocks/stock options in GI on Demand, Modify Health.

Siobhan Proksell, M.D. faculty of this educational activity, has indicated that she has no relevant financial relationships with ineligible companies* to disclose.

Eamonn Quigley, M.D., FRCP, FACP, has indicated that he is a member of the Speakers' Bureau for 4D Pharmaceuticals, Bioamerica, and Vibrant.

Eamonn Quigley, M.D., FRCP, FACP, has indicated that he is a consultant for 4D Pharmaceuticals, Vibrant, Precisionbiotics, Novozymes, Salix, and Allergan. He has also indicated that he is an advisor for Atlanta Foods.

Rajender Reddy, M.D., has indicated that he received Grant/Research support from Mallinckrodt, Exaqt Sciences, Bristol Myer Squibb, and Grifols. He has also indicated that he is a consultant for Pfizer, Mallinckrodt, , and Sparks Therapeutics. He has also indicated that he has a relationship with Novartis DSMB.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*